Table 1.
Demographic, clinical and laboratory findings of patients with thalassemia major in three treatment groups
| Parameter | Deferoxamine group (n=34) | Deferasirox group(n=35) | Combined group * (n=35) | P-value |
|---|---|---|---|---|
| Mean age±SD, years | 25.3 ± 5.1 | 22.2 ± 7.6 | 24.6 ± 5.2 | 0.09 |
| Males, no. (%) | 18 (52.9) | 15(42.9) | 16(45.7) | 0.68 |
| Splenectomy, no. (%) | 20(58.8) | 15(42.9) | 22(62.9) | 0.20 |
| Hepatitis C positive (%) | 9(26.5) | 9(25.7) | 14(40) | 0.34 |
| Myocardial T2*, ms | 12.0±4.1 | 13.0±4.5 | 11.6±3.8 | 0.38 |
| Liver T2*,ms | 5.5±6.6 | 3.4±3.1 | 4.8±5.1 | 0.23 |
| Serum ferritin, ng/ml | 2794±2310 | 3112±2549 | 2817±2134 | 0.81 |
| Hemoglobin, g/dl | 9.4±1.3 | 9.4±1.1 | 9.6±1.3 | 0.78 |
| ANC×109/L | 6.3±2.5 | 5.2±2.6 | 5.0±2.5 | 0.09 |
| Platelets, ×109/L | 510±247 | 473±263 | 463±258 | 0.73 |
| ALT, IU/L | 41±16 | 36±17 | 42±22 | 0.43 |
| AST, IU/L | 38±23 | 41±30 | 51±30 | 0.15 |
| Bilirubin total, mg/dl | 2.5±1.3 | 2.1±1.0 | 1.9±0.8 | 0.03 |
| Creatinine, mg/dl | 0.64±0.19 | 0.69±0.17 | 0.67±0.11 | 0.39 |
*
Deferoxamine + deferiprone